News
News Articles 1 - 10 of 160
Oct
Read more
Friday 11th October 2024
Latest data reinforces calls for extension of opt-out hepatitis B testing and highlights need to resolve inequalities
New data presented today at The British Association for the Study of the Liver Annual Meeting in Harrogate has added weight to calls from the British Liver Trust for opt out blood testing to be made routinely available in all emergency departments across the UK. The research also highlights the urgent need for improvements to ensure adequate follow up and monitoring of patients who have been diagnosed with hepatitis B (HBV).
The British Liver Trust has been calling for the roll out of opt-out testing across all emergency Departments in the UK since testing for HIV, hepatitis B and hepatitis C launched in April 2022 in Emergency Departments in areas of very high HIV diagnosed prevalence. All Emergency Department attendees over 18 years of age who were having blood tests done for any reason, were tested for HIV, hepatitis B and hepatitis C, unless they opted out. The initiative has unearthed a lot more cases of undetected hepatitis B than expected, resulting in a 30% increase in estimated prevalence and surge in demand for hepatitis B services.
Opt-out blood borne virus testing in Emergency departments was rolled out in areas of extremely high HIV prevalence in April 2022. This research described the cases identified through testing at two Emergency Departments in King’s College Hospital NHS Foundation Trust. In the first 18 months, out of the 837 patients who tested positive for viral hepatitis (hepatitis B or C), the majority, 715 (85%) tested positive for hepatitis B. Although 351 (42%) were already in care, almost a quarter (24%) were new diagnoses of hepatitis B, which can cause liver fibrosis, cirrhosis and liver cancer and other serious health complications if left untreated.
56 patients (8%) had previously been diagnosed but were not receiving care or treatment, and a further 40 patients (6%) could not be contacted after the positive test to check that they were aware of their diagnoses. This highlights the need for strategies to ensure that patients with hepatitis B are followed up adequately, which requires information, education and patient involvement. It also identifies the need for research into barriers to accessing care which may include stigma, discrimination and language barriers.
Pamela Healy OBE, Chief Executive at the British Liver Trust said:
“If left undetected, the hepatitis B virus can cause liver damage and increase an individual’s risk of developing liver cancer, yet thousands of people in the UK are asymptomatic and unaware they are infected with it.
This latest research reinforces what we already knew – that opt-out testing is highly effective at identifying people living with previously undiagnosed blood borne viruses, such as hepatitis B and hepatitis C, so that they can receive treatment, prevent further complications and ultimately reduce NHS spending in the long term.”
In England alone, over 200,000 people are estimated to be living with chronic hepatitis B (HBV) – the majority are undiagnosed, unlinked to care and at higher risk of premature death from cirrhosis and liver cancer.
Professor Raj Mookerjee, Secretary of the British Association for the Study of the Liver said:
“The opt-out testing programme in Emergency Departments in England has identified an unprecedented number of new cases of hepatitis B, particularly from disadvantaged groups who are less likely to come forward for routine testing, and whose only interaction with healthcare services has been via emergency departments.
Although the surge in demand for services and access to treatment has added to NHS pressures, wwe must continue to work with policy makers to identify affected patients and address the health inequalities to ensure that everyone has access to the treatment and care that they need.”
Senior author of the research, Dr Kate Childs, King’s College Hospital NHS Foundation Trust said:
“This program has successfully identified a large number of patients with hepatitis B infection, who were either undiagnosed or not in care. Many of those tested live in areas of deprivation and have difficulty in accessing healthcare. This program empowers this group of individuals to attend for hepatitis B care, prevent onwards transmission and reduce the long-term risk of complications including liver cancer. Adequate resources are needed to ensure that hepatitis services are able to review and treat these patients in a timely manner.”
In November 2023, NHS England expanded the scope of opt-out testing for HIV and viral hepatitis in emergency departments to 47 sites across England. The British Liver Trust is calling for opt-out testing to be made routinely available across the UK.
ENDS
FOR MORE INFORMATION OR INTERVIEW REQUESTS CONTACT media@britishlivertrust.org.uk
Sep
Read more
As Chair of the Addiction Mission, Office of Life Sciences, I have been working with the James Lind Alliance to set top priorities for addiction research from the perspective of those with lived/living experience, families & carers and staff working in treatment and recovery services. More information can be found at https://www.jla.nihr.ac.uk/priority-setting-partnerships/addiction-mission/ .
Once the priorities have been determined, they will be discussed with funders to inform their strategy/funding calls. We have already had some preliminary discussions with NIHR and MRC are aware also.
The survey is now live and can be completed online or in paper form. The links are the above website and are also below:
• Complete an online survey
• Complete an easy read online survey
• Download a copy of the easy read survey print it out, write your answers on it and send it back to us by freepost at the address shown in the survey. Or download the easy read survey, type your answers in it, and email it back to us at the address shown in the survey.
The closing date is 8th October 2024.
Professor Anne Lingford-Hughes,
Professor of Addiction Biology,
Head, Division of Psychiatry
Dept of Brain Sciences,
Imperial College London,
Level 2, Commonwealth Bldg
Hammersmith campus,
160 Du Cane Road,
London W12 0NN.
Tel: 020 7594 8682
Chair of the Addiction Mission, Office of Life Sciences
Sep
Read more
NHS England is currently gathering information on the current landscape, approaches and service models for diagnosing Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) formerly known as non-alcoholic fatty liver disease (NAFLD).
We are sharing a link that leads to a short survey to help us understand the barriers, challenges and opportunities from a clinical perspective.
Please complete the survey that takes approximately 10 minutes and can be found here.
Thank you for taking part.
Aug
Read more
- QuestPrehab to begin working with 50 patients requiring liver transplantation
- First prehab service to work remotely with patients waiting on a transplant list
- The year-long trial to focus on anxiety reduction and improvement of liver frailty scores
- Potential to expand the service to patients with other liver diseases
Wednesday 17th July 2024: Kent-based telehealth company QuestPrehab has signed a contract with the University Hospitals Plymouth NHS Trust to deliver digital prehabilitation (‘prehab’) services to liver patients across Devon, Cornwall and Somerset.
The year-long trial with the South West Liver Unit at University Hospitals Plymouth NHS Trust will see QuestPrehab work with 50 patients undergoing assessment and listing for liver transplant. If successful, the service may be expanded to patients living with other liver diseases and who currently are not on the list.
The digital programmes and resources run by the team at QuestPrehab will be specially developed to cater for the clinical and holistic needs of liver patients in collaboration with the Plymouth-based hospital team.
Prehab is a relatively new area of healthcare that focuses on improving the general health and activity of patients before surgery / treatment as a way of aiding their recovery.
Patients who complete their prehab course prior to planned surgery are less likely to be readmitted to hospital, enjoy improved health-related quality of life, return to work earlier and need less involvement with social and primary care providers.
The aim of the trial is to demonstrate two pivotal elements:
- the feasibility of remote delivery of prehab and the benefits in health-related quality of life for patients awaiting liver transplant
- how the usually long waiting time can be utilised in a positive and clinically effective manner … 50% of patients listed for transplant typically have a wait of six months or more
“We’re very excited to have the opportunity to expand much-needed support to our patients here in the south west,” said Professor Matthew Cramp, Consultant Hepatologist at the South West Liver Unit, UHP.
“Liver transplant patients face many challenges and to be able to provide a personalised prehab service while they wait for their surgery is something we’ve been keen to offer for some time. Having the consistency of supervision by a prehab specialist we hope will lead to a lower risk of complications post-transplant and improve quality of life both pre and post-operatively.”
“The signing of this ground-breaking contract with the University Hospitals Plymouth NHS Trust will see us working hand-in-hand with the South West Liver Unit at Derriford Hospital to improve quality of life for their transplant patients,” said QuestPrehab founder Professor Tara Rampal. “Waiting for a liver transplant is an extremely anxious time for all patients. They face the uncertainty of when they will be called up for the transplant whilst also dealing with the consequences of advanced liver disease and the worry that their condition may deteriorate during this time.”
“Patients will receive a highly personalised programme based on four key areas – physical activity, anxiety management, diet advice and lifestyle modifications – with a goal of alleviating their level of anxiety and improving their liver frailty score.”
Each patient will be able to access their individualised programmes via QuestPrehab’s app. Exercise classes and support sessions will be delivered by a combination of phone, Zoom or Skype calls. Those patients who do not have access to suitable technology will be able to loan equipment from the South West Liver Unit during the trial at no cost to themselves.
The 12-month trial will be evaluated through standardised patient reported outcome measures and physical assessment scores.
News of the contract – the first of its kind in the UK – follows QuestPrehab’s recent deal to supply prehab services to two hospitals in China, along with its success in working with NHS oncology patients over the past four years.
Professor Tara Rampal explains: “Our service is scalable and cost efficient, making wide-scale adoption of digital prehab possible. It doesn’t require any modifications to pre-existing infrastructure, processes, patient pathways, or systems, so can be easily inserted into any healthcare provider.”
ENDS
Aug
Read more
We would like to invite all members with an interest in the study of the liver to take part in a Delphi process to develop a Quality Standards Framework for management of liver disease in the UK.
A multi-disciplinary group was set up in order to develop quality standards for the management of people with chronic liver disease, in order to improve and standardise liver disease care across the UK. The group comprised hepatologists, gastroenterologists, trainees, specialist liver nurses, pharmacists, physiotherapists and dieticians, and also included patient/lay representatives. A writing group has developed a set of proposed standards, and we would now like to seek involvement from the wider community of professionals involved in the care of patients with liver disease.
The process will consist of a series of Delphi rounds responding to the proposed standards, including ranking them in terms of importance, relevance and reach.
On behalf of the BSG, BASL and BLNA, we would like to invite all those with interest in the study of the liver to participate in this process.
Participants must be able to commit to the following:
- Completing multiple rounds of Delphi survey (2-3 rounds expected), over the next few months.
All members of the Delphi panel who participate in all rounds will be acknowledged as co-authors on any subsequent publication.
Jul
Read more
The UK National Screening Committee’s (UK NSC’s) 2024 Annual Call for Topics is now open.
During the 3-month annual call, which closes on 30 September 2024, any individual or organisation can submit proposals to the UK NSC for:
- new screening topics
- modifications to, or the ceasing of, existing screening programmes
- early updates to screening topics that the UK NSC has considered in the past 3 years
Proposals can cover population, targeted or risk-stratified screening programmes.
Please refer to the UK NSC annual call: submitting a screening proposal guidance before making a submission.
The 2024 annual call runs from 1 July 2024 to 30 September 2024.
Please email uknsc@dhsc.gov.uk if you have any queries about the annual call process.
Jul
Read more
The European Medicines Association (EMA) issued a statement on Obeticholic acid (Ocaliva) for the treatment of primary biliary cholangitis (PBC) on 28 06 2024.
The EMA has recommended that the marketing authorisation for Ocaliva be revoked in the European Union following results of the COBALT trial, 747-302 . In the UK EMA recommendations do not apply, as we are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). At present, there are no changes to the recommendations on use of Obeticholic acid in PBC from the MHRA or the National Institute for Health and Care Excellence (NICE) and so current prescribing practices should NOT change.
We shall update the UK liver community if there are any changes to the recommendations on the use of Obeticholic acid.
Please find the link to the longer statement to follow > Here .
Jun
Read more
The BASL ArLD special interest group has just launched a national audit (ALERT UK) on the in-patient management of patients with alcohol related liver disease (ArLD). We are keen to get as many sites as possible involved to get a representative sample of current care in the UK.
'ALERT UK' is multicentre retrospective audit and has been endorsed by the BSG, BASL and Torch UK.
In short, we only require data from 20 patients from each site and have a 'pre-coded' spreadsheet based on HES codes to send to your hospital data team to easily identify the patients for inclusion.
All contributors will be named as PubMed citable authors on any publications.
Further information including the full audit protocol can be found here on the BSG website :
https://www.bsg.org.uk/news/alcohol-related-liver-disease-audit-alert-uk
Each site can have up to 4 audit members made up of any of the clinical team involved in the care of inpatients with ArLD ( eg doctors of any grade, nurses, members of alcohol care team, allied health professionals etc)
If you are interested please register your site via this link: https://forms.gle/dj7KKczb9FQ6
Closing in mid-July.
If you have any questions please contact us : alertaudituk@gmail.com .
Please spread the word in your region if you think of others who may be interested in participating.
Jun
Read more
Pabrinex IV will be out of stock from July/ August 2024 until September 2025, due to supply issues relating to manufacturing regulations issued by the EU.
Pabrinex IM will be permanently discontinued from December 2024. Pabrinex is only used in the UK, with thiamine IV/ IM being routinely used globally.
At present the plan is to obtain unlicensed IV and IM thiamine from Europe with dosing guidance available via the SPS link below.
Applications for the licensing of thiamine IM and IV are due to go to the MHRA, which will hopefully be granted before the end of the year.
It is important to note if a Patient Group Direction (PGD) is being used (often used in community setting) only licensed products can be used in this setting. Therefore IM Pabrinex should be conserved for this purpose.
The following has been published online by the DHSC Specialist Pharmacy Service – see link below:
Using and prescribing thiamine in alcohol dependence – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice
Joanna Henry, Gastroenterology Directorate Pharmacist, Liverpool University Hospitals NHS Trust
Sital Shah, Chair British hepatology Pharmacy Group , Consultant Pharmacist, King’s College hospital, London
Jun
Read more
BASL have produced this survey about liver disease service provision in the UK.
We would be extremely grateful if you could complete the short survey (which should take no longer than 10 minutes) using the link below.
We would ask that only one response is completed for each hospital to avoid duplication.
This is part of a larger project which builds on the Lancet Liver Commission, aiming to develop a better understanding of the needs of patients requiring liver disease services across the whole of the care pathway, from early identification to specialist treatment. The national Hepatobiliary & Pancreas Clinical Reference Group (chaired by Professor Richard Aspinall) is leading work to bring about the transformation of liver disease services, reducing inequalities in terms of access, uptake and outcomes and the response to this survey will be used as supporting evidence. As Integrated Care Boards take on more responsibility for commissioning local services, the findings from this survey will clarify where there are gaps in service provision and where there are opportunities to strengthen networks to improve population health outcomes.
Although we are asking for your email address, that is purely for administrative purposes. All responses will be confidential and a final report will be produced which will not enable any individual clinicians or hospitals to be identified.
The final report will be available on the BASL website but if you would like a copy emailed to you separately, please contact angeline.walker@nhs.net .
If you have any queries about the survey, please email michael.allison6@nhs.net or angeline.walker@nhs.net .
Thank you for taking the time to respond.
Please click > HERE to access and take part in the survey.
Thank you.
